$CRVO
CervoMed Inc.

2018 Q3 Form 10-Q Financial Statement

#000143774918020566 Filed on November 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.590M $1.560M
YoY Change 1.92% -59.48%
% of Gross Profit
Research & Development $1.170M $1.759M
YoY Change -33.51% -9.4%
% of Gross Profit
Depreciation & Amortization $30.00K $30.00K
YoY Change 0.0% 200.0%
% of Gross Profit
Operating Expenses $1.170M $1.759M
YoY Change -33.51% -9.4%
Operating Profit -$6.972M -$3.346M
YoY Change 108.37% -42.31%
Interest Expense $37.98K $1.318K
YoY Change 2781.71% -4.35%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change
Pretax Income -$6.934M $5.097M
YoY Change -236.05% -187.86%
Income Tax -$214.5K
% Of Pretax Income
Net Earnings -$6.720M $5.097M
YoY Change -231.84% -193.75%
Net Earnings / Revenue
Basic Earnings Per Share -$1.99 $0.21
Diluted Earnings Per Share $3.371M $0.20
COMMON SHARES
Basic Shares Outstanding 50.57M 13.94M
Diluted Shares Outstanding 50.57M 14.71M

Balance Sheet

Concept 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.02M $1.220M
YoY Change 803.28% -59.6%
Cash & Equivalents $11.02M $1.216M
Short-Term Investments
Other Short-Term Assets $550.0K $11.02M
YoY Change -95.01% 3981.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.57M $12.24M
YoY Change -5.48% 272.45%
LONG-TERM ASSETS
Property, Plant & Equipment $379.2K $479.6K
YoY Change -20.94% 460.49%
Goodwill $2.743M $6.929M
YoY Change -60.41% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $263.5K $38.81K
YoY Change 578.84% -63.58%
Total Long-Term Assets $12.02M $16.09M
YoY Change -25.25% 2.07%
TOTAL ASSETS
Total Short-Term Assets $11.57M $12.24M
Total Long-Term Assets $12.02M $16.09M
Total Assets $23.59M $28.33M
YoY Change -16.71% 48.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $129.1K $409.4K
YoY Change -68.48% -45.95%
Accrued Expenses $820.0K $1.420M
YoY Change -42.25% 36.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $550.0K
YoY Change -100.0% -70.74%
Total Short-Term Liabilities $945.7K $18.69M
YoY Change -94.94% 407.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $945.7K $18.69M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.687M $21.97M
YoY Change -87.77% 190.59%
SHAREHOLDERS EQUITY
Retained Earnings -$74.35M -$63.34M
YoY Change 17.38% 9.94%
Common Stock $95.26M $69.70M
YoY Change 36.67% 0.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.91M $6.357M
YoY Change
Total Liabilities & Shareholders Equity $23.59M $28.33M
YoY Change -16.71% 48.72%

Cashflow Statement

Concept 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$6.720M $5.097M
YoY Change -231.84% -193.75%
Depreciation, Depletion And Amortization $30.00K $30.00K
YoY Change 0.0% 200.0%
Cash From Operating Activities -$1.920M -$3.890M
YoY Change -50.64% 109.14%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$380.0K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 -$380.0K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -1.940M
YoY Change -100.0% -203.19%
NET CHANGE
Cash From Operating Activities -1.920M -3.890M
Cash From Investing Activities 0.000 -380.0K
Cash From Financing Activities 0.000 -1.940M
Net Change In Cash -1.920M -6.210M
YoY Change -69.08% -31150.0%
FREE CASH FLOW
Cash From Operating Activities -$1.920M -$3.890M
Capital Expenditures $0.00 -$380.0K
Free Cash Flow -$1.920M -$3.510M
YoY Change -45.3% 88.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true
CY2017Q4 dffn Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
63350
dffn Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
0
dffn Class Of Warrant Or Rights Expired
ClassOfWarrantOrRightsExpired
421221
CY2018Q3 dffn Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
CY2017Q3 dffn Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
dffn Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
CY2018Q3 dffn Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
47688
CY2018Q3 dffn Dilutive Securities Effect On Basic Earnings Per Share Interest On Convertible Debt
DilutiveSecuritiesEffectOnBasicEarningsPerShareInterestOnConvertibleDebt
dffn Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
-18909792
dffn Proceeds From Issuance Of Convertible Preferred Stock Net Of Offering Costs
ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts
dffn Proceeds From Issuance Of Convertible Preferred Stock Net Of Offering Costs
ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts
22129774
dffn Reclassification Of Accrued Dividends Related To Issuance Of Common Stock To Preferred Stock Holders
ReclassificationOfAccruedDividendsRelatedToIssuanceOfCommonStockToPreferredStockHolders
1148307
CY2017Q3 dffn Dilutive Securities Effect On Basic Earnings Per Share Interest On Convertible Debt
DilutiveSecuritiesEffectOnBasicEarningsPerShareInterestOnConvertibleDebt
28891
dffn Dilutive Securities Effect On Basic Earnings Per Share Interest On Convertible Debt
DilutiveSecuritiesEffectOnBasicEarningsPerShareInterestOnConvertibleDebt
dffn Dilutive Securities Effect On Basic Earnings Per Share Interest On Convertible Debt
DilutiveSecuritiesEffectOnBasicEarningsPerShareInterestOnConvertibleDebt
CY2018Q1 dffn Dividends Makewhole Adjustment
DividendsMakewholeAdjustment
8200000
CY2018Q3 dffn Dividends Makewhole Adjustment
DividendsMakewholeAdjustment
CY2017Q3 dffn Dividends Makewhole Adjustment
DividendsMakewholeAdjustment
dffn Dividends Makewhole Adjustment
DividendsMakewholeAdjustment
8167895
dffn Dividends Makewhole Adjustment
DividendsMakewholeAdjustment
CY2018Q3 dffn Preferential Dividends Payble
PreferentialDividendsPayble
CY2017Q4 dffn Preferential Dividends Payble
PreferentialDividendsPayble
1062314
CY2018Q3 dffn Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
551337
CY2017Q4 dffn Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
769946
dffn Reclassification Of Accrued Dividends Related To Issuance Of Common Stock To Preferred Stock Holders
ReclassificationOfAccruedDividendsRelatedToIssuanceOfCommonStockToPreferredStockHolders
dffn Stock And Warrants Issued During Period Value Net Issuance Costs
StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts
10417520
CY2018Q1 dffn Stock Issued During Period Shares Makewhole Adjustment
StockIssuedDuringPeriodSharesMakewholeAdjustment
11668421
dffn Stock Issued During Period Value Makewhole Adjustment
StockIssuedDuringPeriodValueMakewholeAdjustment
dffn Stock Reclassified Upon Conversion Of Preferred Stock
StockReclassifiedUponConversionOfPreferredStock
dffn Stock Reclassified Upon Conversion Of Preferred Stock
StockReclassifiedUponConversionOfPreferredStock
187172
CY2018Q3 dffn Warrant Expense
WarrantExpense
CY2017Q3 dffn Warrant Expense
WarrantExpense
dffn Warrant Expense
WarrantExpense
dffn Warrant Expense
WarrantExpense
10225846
dffn Warrant Expense Change In Fair Value And Other Financing Expenses
WarrantExpenseChangeInFairValueAndOtherFinancingExpenses
dffn Warrant Expense Change In Fair Value And Other Financing Expenses
WarrantExpenseChangeInFairValueAndOtherFinancingExpenses
5813720
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
129057
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
511956
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
80051
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
122711
CY2018Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
618131
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
312221
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
95210928
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
82770313
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
973950
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
971832
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
327396
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
292501
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
971832
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16529812
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34516809
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3212188
CY2018Q3 us-gaap Assets
Assets
23594668
CY2017Q4 us-gaap Assets
Assets
26145815
CY2018Q3 us-gaap Assets Current
AssetsCurrent
11569778
CY2017Q4 us-gaap Assets Current
AssetsCurrent
9666414
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
11967
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34516809
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11018441
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8896468
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1552852
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1216000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2121973
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-336852
CY2018Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
31303012
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Common Stock Dividends Shares
CommonStockDividendsShares
1032219
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50572001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14519629
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50572001
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14519629
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
50571
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
14520
CY2018Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
CY2017Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
550000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-482425
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
CY2018Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1741253
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2223678
us-gaap Depreciation
Depreciation
81450
us-gaap Depreciation
Depreciation
39767
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P5Y73D
CY2018Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2100000
CY2018Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
26723
CY2017Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
27374
us-gaap Depreciation Nonproduction
DepreciationNonproduction
81450
us-gaap Depreciation Nonproduction
DepreciationNonproduction
39767
us-gaap Dividends
Dividends
85993
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.83
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2018Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
CY2017Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8441616
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-18909792
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1589621
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1559399
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4748090
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4908424
CY2017Q4 us-gaap Goodwill
Goodwill
6929258
CY2018Q3 us-gaap Goodwill
Goodwill
2743208
CY2018Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
4186050
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
4186050
CY2017Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
CY2018Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2017Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6934223
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5096856
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1496150
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-405620
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
661675
CY2018Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13281297
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3154181
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-214493
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-482425
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2018Q3 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
200000
us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
500000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-134202
CY2017Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
816579
CY2018Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
CY2017Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
756376
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
CY2018Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
CY2017Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
20608
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
CY2018Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
8639000
CY2017Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
8639000
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
37981
CY2017Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1318
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
120784
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-73290
us-gaap Interest Paid Net
InterestPaidNet
40142
us-gaap Interest Paid Net
InterestPaidNet
112800
CY2018Q3 us-gaap Interest Payable Current
InterestPayableCurrent
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
37415
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
25000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
50000
CY2018Q3 us-gaap Liabilities
Liabilities
2686930
CY2017Q4 us-gaap Liabilities
Liabilities
4915871
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23594668
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26145815
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
945677
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2690807
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-6719730
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
5096856
us-gaap Net Income Loss
NetIncomeLoss
-12798872
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4067127
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6719730
us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0px" cellpadding="0pt" cellspacing="0pt" style="margin: 0pt; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;"> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></div> </td> <td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-weight: bold;">Organization and Description of Business</div></div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:44pt;">Diffusion Pharmaceuticals Inc. (&#x201c;Diffusion&#x201d; or the &#x201c;Company&#x201d;), a Delaware corporation, is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The Company is developing its lead product candidate, trans sodium crocetinate (&#x201c;TSC&#x201d;) for use in many cancer types in which tumor oxygen deprivation ("hypoxia") is known to diminish the effectiveness of current treatments. TSC is designed to target the cancer&#x2019;s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy. Other possible uses of TSC include the treatment of hypoxic conditions such as stroke, cardiovascular disease, neurodegenerative disease and emergency medicine.</div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9867520
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20151794
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10438604
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7745547
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10050042
us-gaap Net Income Loss
NetIncomeLoss
-3154181
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6719730
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2891861
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21052760
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2920752
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21052760
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-22976919
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6972204
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3346078
us-gaap Operating Income Loss
OperatingIncomeLoss
-13402081
us-gaap Operating Income Loss
OperatingIncomeLoss
-8894611
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
417387
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
39735
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
118519
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
116464
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
114409
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
28260
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
816620
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1628851
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
263480
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
450491
CY2018Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1386
CY2018Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
CY2017Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61554889
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2870226
CY2018Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
70750
CY2017Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
30840
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
428542
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
97980
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
438604
us-gaap Payments To Acquire Restricted Certificates Of Deposit
PaymentsToAcquireRestrictedCertificatesOfDeposit
us-gaap Payments To Acquire Restricted Certificates Of Deposit
PaymentsToAcquireRestrictedCertificatesOfDeposit
10000000
CY2018Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
CY2017Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
8167895
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10846062
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
379202
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
460652
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
550000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1880000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1169810
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1759305
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4386491
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3946420
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-74353761
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.02
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2361007
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2192
us-gaap Share Based Compensation
ShareBasedCompensation
971832
us-gaap Share Based Compensation
ShareBasedCompensation
973950
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.147
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.149
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.024
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
660000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2555989
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3213797
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.32
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.02
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
17.10
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.02
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y208D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y127D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3D
CY2018Q1 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
8306278
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000
us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
1148307
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
20907738
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
21229944
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
21229944
CY2018Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
20907738
CY2018Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
CY2017Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
366641
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
85993
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
912946
CY2018Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2017Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2018Q3 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
CY2017Q3 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
366641
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
85993
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
912946
CY2018Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2017Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
13750000
CY2018Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2017Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
12376329
CY2018Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47777757
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12525707
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50572001
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13937869
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
8306278
CY2018Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
CY2017Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
1838354
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:44pt;">The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim condensed consolidated financial statements, actual results <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim condensed consolidated financial statements in the period they are deemed necessary.</div></div></div></div></div></div></div></div></div></div></div>
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50572001
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14714853
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47777757
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11709128

Files In Submission

Name View Source Status
0001437749-18-020566-index-headers.html Edgar Link pending
0001437749-18-020566-index.html Edgar Link pending
0001437749-18-020566.txt Edgar Link pending
0001437749-18-020566-xbrl.zip Edgar Link pending
dffn-20180930.xml Edgar Link completed
dffn-20180930.xsd Edgar Link pending
dffn-20180930_cal.xml Edgar Link unprocessable
dffn-20180930_def.xml Edgar Link unprocessable
dffn-20180930_lab.xml Edgar Link unprocessable
dffn-20180930_pre.xml Edgar Link unprocessable
dffn20180930_10q.htm Edgar Link pending
ex_127368.htm Edgar Link pending
ex_127369.htm Edgar Link pending
ex_127370.htm Edgar Link pending
ex_127371.htm Edgar Link pending
ex_127455.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending